RT Journal Article
SR Electronic
T1 Evaluation of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients in outbreak on a cruise ship
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21253064
DO 10.1101/2021.03.10.21253064
A1 Kaku, Norihito
A1 Nishimura, Fumitaka
A1 Shigeishi, Yui
A1 Tachiki, Rina
A1 Sakai, Hironori
A1 Sasaki, Daisuke
A1 Ota, Kenji
A1 Sakamoto, Kei
A1 Kosai, Kosuke
A1 Hasegawa, Hiroo
A1 Izumikawa, Koichi
A1 Ariyoshi, Koya
A1 Mukae, Hiroshi
A1 Yasuda, Jiro
A1 Morita, Kouichi
A1 Kohno, Shigeru
A1 Yanagihara, Katsunori
YR 2021
UL http://medrxiv.org/content/early/2021/03/16/2021.03.10.21253064.abstract
AB Background A few studies on antibody testing have focused on asymptomatic or mild coronavirus disease 2019 (COVID-19) patients with low initial anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses. Anti-SARS-CoV-2 antibody-testing performance was evaluated using blood samples from asymptomatic or mild COVID-19 patients.Methods Blood samples were collected from 143 COVID-19 patients during an outbreak on a cruise ship 3 weeks after diagnosis. Simultaneously, a second SARS-CoV-2 genetic test was performed. Samples stored before the COVID-19 pandemic were also used to evaluate the lateral flow immunochromatographic assay (LFA) and electrochemiluminescence immunoassay (ECLIA). Titers of anti-SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid and spike proteins were measured using the enzyme-linked immunosorbent assay to compare false-negative- with positive-result samples.Results Sensitivity, specificity, positive-predictive, and negative-predictive values of LFA-detected IgM antibodies were 0.231, 1.000, 1.000, and 0.613, respectively; those of LFA-detected IgG antibodies were 0.483, 0.989, 0.972, and 0.601, respectively; and those of ECLIA-detected total antibodies were 0.783, 1.000, 1.000, and 0.848, respectively. IgM-, IgG-, and total-antibody positivity rates in the patients with negative results from the second genetic testing were 22.9%, 47.6%, and 72.4%, respectively. All antibody titers, especially those of the IgG antibody against nucleocapsid protein, were significantly lower in blood samples with false-negative results than in those with positive results.Conclusions These findings suggest that anti-SARS-CoV-2 antibody testing has lower performance in asymptomatic or mild COVID-19 patients than required in the guidelines, and situations in which it is useful are limited.Key points Anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients is lower than the required clinical sensitivity, although it may be useful in patients at 3–4 weeks after symptom onset but with negative SARS-CoV-2 genetic test results.Competing Interest StatementHironori Sakai is an employee of Cellspect Co., Ltd., and performed ELISA in this study. Norihito Kaku and Kosuke Kosai received research funding from Roche Diagnostics K. K.. Katsunori Yanagihara received research funding from Cellspect Co., Ltd., Roche Diagnostics K. K. and, Abbott Japan LLCClinical TrialUMIN000040402Funding StatementThis research was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP20he0622041.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was approved by the Ethics Committee of Nagasaki University Hospital (20052101) and was registered in the UMIN Clinical Trials Registry (UMIN000040402). Data regarding SARS-CoV-2 RT-PCR results and blood samples were anonymized and individually numbered when they were collected from the cruise ship. Blood samples for the negative controls were stored anonymously at the Department of Laboratory Medicine, Nagasaki University Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at Nagasaki University Hospital. Derived data supporting the findings of this study are available from the corresponding author upon request.